Experts discuss the SWOG S1512 trial of desmoplastic melanoma and the greater relevance of trials of immunotherapy in rare disease states.
April 2026
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
2
Considering Immunotherapy Rechallenge and TILs for Recurrent Mucosal Melanoma
3
B7-H3–Targeted ADC Risvutatug Rezetecan Extends Survival in Small Cell Lung Cancer
4
FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Tumors
5